StreetInsider.com News Articles

Crescita Reports Third Quarter 2025 Results

Wed, 05 Nov 2025 07:30:00 -0500

LAVAL, Quebec--(BUSINESS WIRE)-- Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the third quarter ended September 30, 2025 (“Q3-2025”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board.

Financial Highlights

Q3-2025 vs. Q3-2024

Revenue was $5,393 compared to $3,594, an increase of $1,799;
Gross profit was $2,855 compared to $1,967, an increase of $888;
Operating expenses were $3,017 compared to $3,139, a

Crescita Reports Third Quarter 2025 Results

Wed, 05 Nov 2025 07:30:00 -0500

Financial Highlights

Q3-2025 vs. Q3-2024

Revenue was $5,393 compared to $3,594, an increase of $1,799;
Gross profit was $2,855 compared to $1,967, an increase of $888;
Operating expenses were $3,017 compared to $3,139, a

Crescita Reports Third Quarter 2025 Results

Wed, 05 Nov 2025 07:30:00 -0500

Financial Highlights

Q3-2025 vs. Q3-2024

Revenue was $5,393 compared to $3,594, an increase of $1,799;
Gross profit was $2,855 compared to $1,967, an increase of $888;
Operating expenses were $3,017 compared to $3,139, a

Crescita Reports Third Quarter 2025 Results

Wed, 05 Nov 2025 07:30:00 -0500

Financial Highlights

Q3-2025 vs. Q3-2024

Revenue was $5,393 compared to $3,594, an increase of $1,799;
Gross profit was $2,855 compared to $1,967, an increase of $888;
Operating expenses were $3,017 compared to $3,139, a

Crescita Reports Third Quarter 2025 Results

Wed, 05 Nov 2025 07:30:00 -0500

Financial Highlights

Q3-2025 vs. Q3-2024

Revenue was $5,393 compared to $3,594, an increase of $1,799;
Gross profit was $2,855 compared to $1,967, an increase of $888;
Operating expenses were $3,017 compared to $3,139, a

Crescita Reports Third Quarter 2025 Results

Wed, 05 Nov 2025 07:30:00 -0500

Financial Highlights

Q3-2025 vs. Q3-2024

Revenue was $5,393 compared to $3,594, an increase of $1,799;
Gross profit was $2,855 compared to $1,967, an increase of $888;
Operating expenses were $3,017 compared to $3,139, a

Crescita Reports Third Quarter 2025 Results

Wed, 05 Nov 2025 07:30:00 -0500

Financial Highlights

Q3-2025 vs. Q3-2024

Revenue was $5,393 compared to $3,594, an increase of $1,799;
Gross profit was $2,855 compared to $1,967, an increase of $888;
Operating expenses were $3,017 compared to $3,139, a

Crescita Reports Third Quarter 2025 Results

Wed, 05 Nov 2025 07:30:00 -0500

Financial Highlights

Q3-2025 vs. Q3-2024

Revenue was $5,393 compared to $3,594, an increase of $1,799;
Gross profit was $2,855 compared to $1,967, an increase of $888;
Operating expenses were $3,017 compared to $3,139, a

Crescita Reports Third Quarter 2025 Results

Wed, 05 Nov 2025 07:30:00 -0500

Financial Highlights

Q3-2025 vs. Q3-2024

Revenue was $5,393 compared to $3,594, an increase of $1,799;
Gross profit was $2,855 compared to $1,967, an increase of $888;
Operating expenses were $3,017 compared to $3,139, a

Crescita Reports Third Quarter 2025 Results

Wed, 05 Nov 2025 07:30:00 -0500

Financial Highlights

Q3-2025 vs. Q3-2024

Revenue was $5,393 compared to $3,594, an increase of $1,799;
Gross profit was $2,855 compared to $1,967, an increase of $888;
Operating expenses were $3,017 compared to $3,139, a

Crescita Reports Third Quarter 2025 Results

Wed, 05 Nov 2025 07:30:00 -0500

Financial Highlights

Q3-2025 vs. Q3-2024

Revenue was $5,393 compared to $3,594, an increase of $1,799;
Gross profit was $2,855 compared to $1,967, an increase of $888;
Operating expenses were $3,017 compared to $3,139, a

Crescita Reports Third Quarter 2025 Results

Wed, 05 Nov 2025 07:30:00 -0500

Financial Highlights

Q3-2025 vs. Q3-2024

Revenue was $5,393 compared to $3,594, an increase of $1,799;
Gross profit was $2,855 compared to $1,967, an increase of $888;
Operating expenses were $3,017 compared to $3,139, a

Crescita Reports Second Quarter 2025 Results

Wed, 06 Aug 2025 08:00:00 -0500

LAVAL, Quebec--(BUSINESS WIRE)-- Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the second quarter ended June 30, 2025 (“Q2-2025”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board.

Financial Highlights

Q2-2025 vs. Q2-2024

Revenue was $6,233 compared to $4,088, an increase of $2,145;
Gross profit was $3,825 compared to $2,235, an increase of $1,590;
Operating expenses were $3,242 compared to $3,279, a

Crescita Reports Second Quarter 2025 Results

Wed, 06 Aug 2025 08:00:00 -0500

LAVAL, Quebec--(BUSINESS WIRE)-- Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the second quarter ended June 30, 2025 (“Q2-2025”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board.

Financial Highlights

Q2-2025 vs. Q2-2024

Revenue was $6,233 compared to $4,088, an increase of $2,145;
Gross profit was $3,825 compared to $2,235, an increase of $1,590;
Operating expenses were $3,242 compared to $3,279, a

Crescita Reports Second Quarter 2025 Results

Wed, 06 Aug 2025 08:00:00 -0500

LAVAL, Quebec--(BUSINESS WIRE)-- Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the second quarter ended June 30, 2025 (“Q2-2025”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board.

Financial Highlights

Q2-2025 vs. Q2-2024

Revenue was $6,233 compared to $4,088, an increase of $2,145;
Gross profit was $3,825 compared to $2,235, an increase of $1,590;
Operating expenses were $3,242 compared to $3,279, a

Crescita Reports Second Quarter 2025 Results

Wed, 06 Aug 2025 08:00:00 -0500

LAVAL, Quebec--(BUSINESS WIRE)-- Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the second quarter ended June 30, 2025 (“Q2-2025”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board.

Financial Highlights

Q2-2025 vs. Q2-2024

Revenue was $6,233 compared to $4,088, an increase of $2,145;
Gross profit was $3,825 compared to $2,235, an increase of $1,590;
Operating expenses were $3,242 compared to $3,279, a

Crescita Reports Second Quarter 2025 Results

Wed, 06 Aug 2025 08:00:00 -0500

LAVAL, Quebec--(BUSINESS WIRE)-- Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the second quarter ended June 30, 2025 (“Q2-2025”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board.

Financial Highlights

Q2-2025 vs. Q2-2024

Revenue was $6,233 compared to $4,088, an increase of $2,145;
Gross profit was $3,825 compared to $2,235, an increase of $1,590;
Operating expenses were $3,242 compared to $3,279, a

Crescita Reports Second Quarter 2025 Results

Wed, 06 Aug 2025 08:00:00 -0500

LAVAL, Quebec--(BUSINESS WIRE)-- Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the second quarter ended June 30, 2025 (“Q2-2025”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board.

Financial Highlights

Q2-2025 vs. Q2-2024

Revenue was $6,233 compared to $4,088, an increase of $2,145;
Gross profit was $3,825 compared to $2,235, an increase of $1,590;
Operating expenses were $3,242 compared to $3,279, a

Crescita Reports Second Quarter 2025 Results

Wed, 06 Aug 2025 08:00:00 -0500

LAVAL, Quebec--(BUSINESS WIRE)-- Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the second quarter ended June 30, 2025 (“Q2-2025”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board.

Financial Highlights

Q2-2025 vs. Q2-2024

Revenue was $6,233 compared to $4,088, an increase of $2,145;
Gross profit was $3,825 compared to $2,235, an increase of $1,590;
Operating expenses were $3,242 compared to $3,279, a

Crescita Reports Second Quarter 2025 Results

Wed, 06 Aug 2025 08:00:00 -0500

LAVAL, Quebec--(BUSINESS WIRE)-- Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the second quarter ended June 30, 2025 (“Q2-2025”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board.

Financial Highlights

Q2-2025 vs. Q2-2024

Revenue was $6,233 compared to $4,088, an increase of $2,145;
Gross profit was $3,825 compared to $2,235, an increase of $1,590;
Operating expenses were $3,242 compared to $3,279, a

Crescita Reports Second Quarter 2025 Results

Wed, 06 Aug 2025 08:00:00 -0500

LAVAL, Quebec--(BUSINESS WIRE)-- Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the second quarter ended June 30, 2025 (“Q2-2025”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board.

Financial Highlights

Q2-2025 vs. Q2-2024

Revenue was $6,233 compared to $4,088, an increase of $2,145;
Gross profit was $3,825 compared to $2,235, an increase of $1,590;
Operating expenses were $3,242 compared to $3,279, a

Crescita Reports Second Quarter 2025 Results

Wed, 06 Aug 2025 08:00:00 -0500

LAVAL, Quebec--(BUSINESS WIRE)-- Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the second quarter ended June 30, 2025 (“Q2-2025”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board.

Financial Highlights

Q2-2025 vs. Q2-2024

Revenue was $6,233 compared to $4,088, an increase of $2,145;
Gross profit was $3,825 compared to $2,235, an increase of $1,590;
Operating expenses were $3,242 compared to $3,279, a

Crescita Reports Second Quarter 2025 Results

Wed, 06 Aug 2025 08:00:00 -0500

LAVAL, Quebec--(BUSINESS WIRE)-- Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the second quarter ended June 30, 2025 (“Q2-2025”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board.

Financial Highlights

Q2-2025 vs. Q2-2024

Revenue was $6,233 compared to $4,088, an increase of $2,145;
Gross profit was $3,825 compared to $2,235, an increase of $1,590;
Operating expenses were $3,242 compared to $3,279, a

Crescita Reports Second Quarter 2025 Results

Wed, 06 Aug 2025 08:00:00 -0500

LAVAL, Quebec--(BUSINESS WIRE)-- Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the second quarter ended June 30, 2025 (“Q2-2025”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board.

Financial Highlights

Q2-2025 vs. Q2-2024

Revenue was $6,233 compared to $4,088, an increase of $2,145;
Gross profit was $3,825 compared to $2,235, an increase of $1,590;
Operating expenses were $3,242 compared to $3,279, a

Crescita Therapeutics (CTX) announce voting results from AGM

Thu, 05 Jun 2025 08:21:25 -0500

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 4, 2025. The detailed results of the votes received by proxy are as follows:

Election of Directors

Director Nominees	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST